These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 8648761)

  • 41. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates.
    Hermida L; Bernardo L; Martín J; Alvarez M; Prado I; López C; Sierra Bde L; Martínez R; Rodríguez R; Zulueta A; Pérez AB; Lazo L; Rosario D; Guillén G; Guzmán MG
    Vaccine; 2006 Apr; 24(16):3165-71. PubMed ID: 16490289
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Induction of neutralizing antibodies and partial protection from viral challenge in Macaca fascicularis immunized with recombinant dengue 4 virus envelope glycoprotein expressed in Pichia pastoris.
    Guzmán MG; Rodríguez R; Rodríguez R; Hermida L; Alvarez M; Lazo L; Muné M; Rosario D; Valdés K; Vázquez S; Martinez R; Serrano T; Paez J; Espinosa R; Pumariega T; Guillén G
    Am J Trop Med Hyg; 2003 Aug; 69(2):129-34. PubMed ID: 13677367
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus.
    Raviprakash K; Wang D; Ewing D; Holman DH; Block K; Woraratanadharm J; Chen L; Hayes C; Dong JY; Porter K
    J Virol; 2008 Jul; 82(14):6927-34. PubMed ID: 18480438
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neutralizing antibodies respond to a bivalent dengue DNA vaccine or/and a recombinant bivalent antigen.
    Zhang ZS; Weng YW; Huang HL; Zhang JM; Yan YS
    Mol Med Rep; 2015 Feb; 11(2):1009-16. PubMed ID: 25371092
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genetic determinants responsible for acquisition of dengue type 2 virus mouse neurovirulence.
    Bray M; Men R; Tokimatsu I; Lai CJ
    J Virol; 1998 Feb; 72(2):1647-51. PubMed ID: 9445071
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques.
    Osorio JE; Brewoo JN; Silengo SJ; Arguello J; Moldovan IR; Tary-Lehmann M; Powell TD; Livengood JA; Kinney RM; Huang CY; Stinchcomb DT
    Am J Trop Med Hyg; 2011 Jun; 84(6):978-87. PubMed ID: 21633037
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys.
    Men R; Bray M; Clark D; Chanock RM; Lai CJ
    J Virol; 1996 Jun; 70(6):3930-7. PubMed ID: 8648730
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein.
    Mota J; Acosta M; Argotte R; Figueroa R; Méndez A; Ramos C
    Vaccine; 2005 May; 23(26):3469-76. PubMed ID: 15837370
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers.
    Wright PF; Ankrah S; Henderson SE; Durbin AP; Speicher J; Whitehead SS; Murphy BR; Pletnev AG
    Vaccine; 2008 Feb; 26(7):882-90. PubMed ID: 18207289
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
    Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
    Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development.
    Huang CY; Butrapet S; Tsuchiya KR; Bhamarapravati N; Gubler DJ; Kinney RM
    J Virol; 2003 Nov; 77(21):11436-47. PubMed ID: 14557629
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Attenuation and immunogenicity of recombinant yellow fever 17D-dengue type 2 virus for rhesus monkeys.
    Galler R; Marchevsky RS; Caride E; Almeida LF; Yamamura AM; Jabor AV; Motta MC; Bonaldo MC; Coutinho ES; Freire MS
    Braz J Med Biol Res; 2005 Dec; 38(12):1835-46. PubMed ID: 16302098
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques.
    Raviprakash K; Porter KR; Kochel TJ; Ewing D; Simmons M; Phillips I; Murphy GS; Weiss WR; Hayes CG
    J Gen Virol; 2000 Jul; 81(Pt 7):1659-67. PubMed ID: 10859370
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Yellow fever virus/dengue-2 virus and yellow fever virus/dengue-4 virus chimeras: biological characterization, immunogenicity, and protection against dengue encephalitis in the mouse model.
    Chambers TJ; Liang Y; Droll DA; Schlesinger JJ; Davidson AD; Wright PJ; Jiang X
    J Virol; 2003 Mar; 77(6):3655-68. PubMed ID: 12610141
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Solution structure of the envelope protein domain III of dengue-4 virus.
    Volk DE; Lee YC; Li X; Thiviyanathan V; Gromowski GD; Li L; Lamb AR; Beasley DW; Barrett AD; Gorenstein DG
    Virology; 2007 Jul; 364(1):147-54. PubMed ID: 17395234
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genetically modified, live attenuated dengue virus type 3 vaccine candidates.
    Blaney JE; Hanson CT; Firestone CY; Hanley KA; Murphy BR; Whitehead SS
    Am J Trop Med Hyg; 2004 Dec; 71(6):811-21. PubMed ID: 15642976
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dengue-4 vaccine: neurovirulence, viraemia and immune responses in rhesus and cynomolgus monkeys.
    Angsubhakorn S; Yoksan S; Bhamarapravati N; Moe JB; Marchette NJ; Pradermwong A; Sahaphong S
    Trans R Soc Trop Med Hyg; 1988; 82(5):746-9. PubMed ID: 3252595
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dengue-2 vaccine: viremia and immune responses in rhesus monkeys.
    Scott RM; Nisalak A; Eckels KH; Tingpalapong M; Harrison VR; Gould DJ; Chapple FE; Russell PK
    Infect Immun; 1980 Jan; 27(1):181-6. PubMed ID: 6766903
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dengue type four viruses with E-Glu345Lys adaptive mutation from MRC-5 cells induce low viremia but elicit potent neutralizing antibodies in rhesus monkeys.
    Lin HH; Lee HC; Li XF; Tsai MJ; Hsiao HJ; Peng JG; Sue SC; Qin CF; Wu SC
    PLoS One; 2014; 9(6):e100130. PubMed ID: 24959738
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Generation and preclinical evaluation of a DENV-1/2 prM+E chimeric live attenuated vaccine candidate with enhanced prM cleavage.
    Keelapang P; Nitatpattana N; Suphatrakul A; Punyahathaikul S; Sriburi R; Pulmanausahakul R; Pichyangkul S; Malasit P; Yoksan S; Sittisombut N
    Vaccine; 2013 Oct; 31(44):5134-40. PubMed ID: 23973247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.